ClinicalTrials.gg
Drug

Interleukin 1 Receptor Antagonist Protein clinical trials

Also written Anakinra and Kineret.

Its developmentBy Amgen, Swedish Orphan Biovitrum and Hamad Medical, step by step14 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.
studies test it
168
open now
26
in phase 3
35
first study started
2000

How each study uses Interleukin 1 Receptor Antagonist Protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Interleukin 1 Receptor Antagonist Protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Nov 2001 · KINERET · BLA 103950 (FDA, Drugs@FDA)
European Union
8 Mar 2002 · Kineret · EMEA/H/C/000363 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Kinaret
8
IL-1Ra
6
rIL-1ra
6
rIL1RN
6
Anakinra (Kineret®)
6

Brand

Kineret
82

Development codes

AMG 719
1

Other names

Anakinra
114
Anakinra 100 mg
2

Studies by the year they started

164 studies that test it; most in 2020 (26); 1 more planned to start later

Studies that test Interleukin 1 Receptor Antagonist Protein, by start year
YearStudies
20001
20011
20022
20033
20042
20052
20061
20085
20093
20102
201111
20126
20136
201411
20154
201610
201711
20184
201911
202026
20217
20229
20236
20243
20255
202612

By phase

A phase 1/2 study counts in both.

Early Phase 1
6
Phase 1
39
Phase 2
103
Phase 3
35
Phase 4
9
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 154

Virginia Commonwealth University (16) · Assistance Publique - Hôpitaux de Paris (10) · University Hospital, Basel, Switzerland (8) · Radboud University Medical Center (8) · Hellenic Institute for the Study of Sepsis (7) · Amgen (7) · Swedish Orphan Biovitrum (6) · University of California, San Diego (4)

Often tested with

Tested in the same studies.

Tocilizumab (12) · Baricitinib (4) · Empagliflozin (3) · Dexamethasone (3) · Hydroxychloroquine (3) · Adalimumab (2) · Ustekinumab (2) · Secukinumab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 3 in phase 3

Studies that test Interleukin 1 Receptor Antagonist Protein, phase 3 first.

Studies

Open first, then newest update. How each study uses Interleukin 1 Receptor Antagonist Protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 168

See all 168 studies that test Interleukin 1 Receptor Antagonist Protein →

Given beside what is tested · 6 — Interleukin 1 Receptor Antagonist Protein is usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with Interleukin 1 Receptor Antagonist Protein

What changed recently

From the registry's own updates since Oct 19, 2026.

Codes

What other systems call Interleukin 1 Receptor Antagonist Protein · ClinicalTrials.gg INT008888

  • MeSH (NLM) D053590Interleukin 1 Receptor Antagonist ProteinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 9013DUQ28KANAKINRAConfirmed FDA, NLM
  • RxNorm 72435One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.